The stock price of Cardiff Oncology Inc (NASDAQ: CRDF) has dropped by -4.51 compared to previous close of 2.33. Despite this, the company has seen a fall of -9.18% in its stock price over the last five trading days. globenewswire.com reported 2024-05-29 that SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a company presentation and 1×1 investor meetings at the Jefferies Healthcare Conference, which is taking place at the Marriott Marquis in New York from June 5-6, 2024.
Is It Worth Investing in Cardiff Oncology Inc (NASDAQ: CRDF) Right Now?
Moreover, the 36-month beta value for CRDF is 1.93. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRDF is 41.11M and currently, short sellers hold a 9.82% of that float. On June 28, 2024, CRDF’s average trading volume was 692.98K shares.
CRDF’s Market Performance
The stock of Cardiff Oncology Inc (CRDF) has seen a -9.18% decrease in the past week, with a -30.47% drop in the past month, and a -58.33% fall in the past quarter. The volatility ratio for the week is 6.99%, and the volatility levels for the past 30 days are at 6.91% for CRDF. The simple moving average for the past 20 days is -19.35% for CRDF’s stock, with a -10.36% simple moving average for the past 200 days.
Analysts’ Opinion of CRDF
Robert W. Baird, on the other hand, stated in their research note that they expect to see CRDF reach a price target of $19. The rating they have provided for CRDF stocks is “Outperform” according to the report published on December 08th, 2021.
Maxim Group gave a rating of “Buy” to CRDF, setting the target price at $20 in the report published on August 09th of the previous year.
CRDF Trading at -34.05% from the 50-Day Moving Average
After a stumble in the market that brought CRDF to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.34% of loss for the given period.
Volatility was left at 6.91%, however, over the last 30 days, the volatility rate increased by 6.99%, as shares sank -29.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.22% lower at present.
During the last 5 trading sessions, CRDF fell by -8.57%, which changed the moving average for the period of 200-days by +26.91% in comparison to the 20-day moving average, which settled at $2.71. In addition, Cardiff Oncology Inc saw 50.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRDF starting from PACE GARY W, who purchase 30,000 shares at the price of $1.37 back on Dec 19 ’23. After this action, PACE GARY W now owns 697,761 shares of Cardiff Oncology Inc, valued at $41,100 using the latest closing price.
Stock Fundamentals for CRDF
Current profitability levels for the company are sitting at:
- -72.61 for the present operating margin
- 0.33 for the gross margin
The net margin for Cardiff Oncology Inc stands at -65.95. The total capital return value is set at -0.71. Equity return is now at value -51.12, with -44.55 for asset returns.
Based on Cardiff Oncology Inc (CRDF), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -15.01. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -53.43.
Currently, EBITDA for the company is -45.01 million with net debt to EBITDA at 0.38. When we switch over and look at the enterprise to sales, we see a ratio of 136.92. The receivables turnover for the company is 1.55for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.91.
Conclusion
To wrap up, the performance of Cardiff Oncology Inc (CRDF) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
